Table 1.

Search strategies used in this review

Searching PubMed (using the “Advanced Search” interface) Chemotherapy–targeted therapy–pharmacovigilance ((((“targeted therapy” OR Molecular Targeted Therapy[MH] OR target*[ti] OR “Antineoplastic Agents/adverse effects”[Mesh] OR “Antineoplastic Agents/toxicity”[Mesh] OR chemotherap*[tiab]) AND (cancer OR tumor OR tumour OR carcinoma OR lymphoma OR sarcoma OR oncology OR ONCOLOG*[TIAB] OR leukemia)) OR NEOPLASMS/DRUG THERAPY[MH]) AND (pharmacovigilance OR Adverse Drug Reaction Reporting Systems[MH] OR pharmacovigilan*[ti] OR Drug-Related Side Effects and Adverse Reactions[MH] OR adverse[ti] OR toxicit*[ti])) AND 2012:2018[dp] Radiotherapy–pharmacovigilance (((radiation[ti] OR “Radiotherapy”[Mesh] OR “Radiation, Ionizing/adverse effects”[Mesh] OR radiotherap*[tiab]) AND (cancer OR tumor OR tumour OR carcinoma OR lymphoma OR sarcoma OR oncology OR ONCOLOG*[TIAB])) OR NEOPLASMS/radiotherapy[MH]) AND (pharmacovigilance OR Adverse Drug Reaction Reporting Systems[MH] OR pharmacovigilan*[ti] OR Drug-Related Side Effects and Adverse Reactions[MH] OR adverse[ti] OR toxicit*[ti]) AND 2012:2018[dp] Searching Scopus (using the “Advanced Search” tools) Chemotherapy–targeted therapy–pharmacovigilance (TITLE-ABS-KEY (“targeted therapy” OR target* OR antineoplastic OR chemotherap*) AND TITLE-ABS-KEY (cancer OR tumor OR tumour OR carcinoma OR lymphoma OR sarcoma OR oncology OR oncolog* OR leukemia) AND TITLE (pharmacovigilance OR “Adverse Drug Reaction” OR pharmacovigilan* OR “Side Effects” OR adverse OR toxicit*)) AND NOT ((INDEX (medline)) OR TITLE-ABS-KEY (radiotherap* OR radiation)) AND (LIMIT-TO (PUBYEAR, 2018) OR LIMIT-TO (PUBYEAR, 2017) OR LIMIT-TO (PUBYEAR, 2016) OR LIMIT-TO (PUBYEAR, 2015) OR LIMIT-TO (PUBYEAR, 2014) OR LIMIT-TO (PUBYEAR, 2013) OR LIMIT-TO (PUBYEAR, 2012)) Radiotherapy (TITLE-ABS-KEY (radiotherap* OR radiation) AND TITLE-ABS-KEY (cancer OR tumor OR tumour OR carcinoma OR lymphoma OR sarcoma OR oncology OR oncolog* OR leukemia) AND TITLE (pharmacovigilance OR “Adverse Drug Reaction” OR pharmacovigilan* OR “Side Effects” OR adverse OR toxicit*)) AND NOT ((INDEX (medline)) OR TITLE-ABS-KEY (“targeted therapy” OR target* OR antineoplastic OR chemotherap*)) AND (LIMIT-TO (PUBYEAR, 2018) OR LIMIT-TO (PUBYEAR, 2017) OR LIMIT-TO (PUBYEAR, 2016) OR LIMIT-TO (PUBYEAR, 2015) OR LIMIT-TO (PUBYEAR, 2014) OR LIMIT-TO (PUBYEAR, 2013) OR LIMIT-TO (PUBYEAR, 2012))